France counted about 16,000 new pancreatic cancer cases in 2023, with incidence doubling in men and tripling in women over 30 years.
Pancreatic cancer cases in France have tripled in two decades, according to the ARC Foundation for Cancer Research, and the disease now strikes women almost as often as men — a shift researchers say they cannot yet fully explain.
Dr. Nelson Dusetti, research director at Inserm and team leader at the Centre de Recherche en Cancérologie de Marseille (CRCM), laid out the risk factors in an interview Journal des Femmes Santé published on Wednesday, World Pancreatic Cancer Day, according to Journaldesfemmes. “The incidence is rising more in women than in men. Today we are almost at parity in the number of cases,” he told the outlet.
The stakes are stark. Five-year survival stands at 11 percent, and 80 percent of diagnoses come at an advanced stage, Sud Ouest reported. In France, cases rose 4.3 percent among women and 5.3 percent among men between 1998 and 2017, according to Sud Ouest.
Smoking causes up to 30 percent of pancreatic cancers
- Smoking is the leading modifiable risk factor, blamed for an estimated 20 to 30 percent of pancreatic cancers.
- Only 5 to 10 percent of cases trace to inherited genetic predisposition — mutations present at birth that raise risk without making cancer inevitable.
- A new European-approved drug roughly doubles median survival in one patient group, but it is not a cure.
The numbers behind the rise
France counted about 16,000 new cases in 2023, with incidence climbing 2.5 percent a year — a rate that has doubled in men and tripled in women over 30 years, France 3 Régions reported. The disease remains concentrated in people over 70, yet incidence is also rising among younger adults, including the 20–39 age group.

Dusetti flagged the trend in younger patients and women as the one worrying the medical community and health authorities, because its causes remain poorly understood. Type 2 diabetes adds complexity: long-standing diabetes raises risk, while newly diagnosed diabetes can sometimes be a consequence of an undetected tumor. Chronic pancreatitis and regular heavy alcohol use — which inflames the pancreas — round out the list, alongside obesity’s metabolic and inflammatory disruptions.
“The goal is not to make people living with obesity, smokers or alcohol consumers feel guilty, nor to stoke fear. It is above all to inform and raise awareness, without judgment or alarmism,” Dusetti said.
Why diagnosis comes so late
The pancreas sits deep in the abdomen, so tumors grow silently. Sud Ouest listed nine warning signs: jaundice, when a tumor compresses the bile duct; abdominal pain; mid-back pain; new-onset diabetes; thrombosis, since the cancer promotes clotting; fatty, frequent stools from disrupted digestive enzymes; unexplained weight loss; nausea or vomiting from duodenal compression; and depression, which the biological and inflammatory changes of the cancer can influence.

Access to scanners, MRI and endoscopic procedures quickly is the bottleneck. “Too much time elapsed between the first symptoms, the first tests and arrival at the consultation,” said Pr Fabrice Muscari, digestive surgeon at the CHU de Toulouse, as quoted by La Dépêche.
What is changing for patients
Dusetti’s team built Pancreas-View, a tool that analyzes a tumor’s gene expression to predict which chemotherapy it will respond to. Retrospective studies showed patients whose treatment matched the predicted sensitivity lived longer. To confirm this prospectively, a national clinical trial called NeoPREDICT has just launched, coordinated by the Institut Paoli-Calmettes in Marseille with Dusetti’s team — aiming to spare patients toxic, potentially ineffective regimens.

In Toulouse, three research avenues target the tumor’s thick fibrous collagen barrier, which blocks immune cells from penetrating — a key reason immunotherapy often fails here. One team, led by Inserm research director Pierre Cordelier, showed in 2024 that a veterinary vaccine virus, harmless to humans, can infect pancreatic cancer cells and trigger immune-mediated elimination.
Another will screen more than 3,000 compounds already in clinical use. The three Toulouse projects, selected in 2025, carry total funding of 1,491,000 euros from the ARC Foundation, which has financed 32 projects in 16 French cities for more than 18 million euros since 2022, including five new projects worth 2.6 million euros selected in October 2026, France 3 Régions reported.
The drug Europe just fast-tracked
On Wednesday, an oral treatment developed by the American company Revolution Medicines received European authorization in record time, Le Tribunal du Net reported. In the trial, median survival among treated patients reached 13.2 months versus 6.7 months on standard chemotherapy — nearly double, though the drug does not cure the disease.
| Measure | Figure | Source |
|---|---|---|
| New cases in France, 2023 | ~16,000 | France 3 Régions |
| Annual incidence growth | 2.5% | France 3 Régions |
| Five-year survival | 11% | Sud Ouest / La Dépêche |
| Diagnoses at advanced stage | 80% | Sud Ouest |
| Cases attributable to smoking | 20–30% | Journal des Femmes Santé |
| Hereditary predisposition cases | 5–10% | Journal des Femmes Santé |
| Median survival, new drug vs. chemotherapy | 13.2 vs. 6.7 months | Le Tribunal du Net |
Who gets access, and when
European authorization is one step; French patient access now depends on the HAS and the early-access calendar, Le Tribunal du Net reported. Meanwhile, the CHU de Toulouse is launching O2CaPan, a coordinated care pathway across seven hospitals in western Occitanie backed by the regional health agency, operational from early 2027, La Dépêche reported.
Pr Muscari warned that the cancer is on track to become the world’s second-leading cause of cancer death within ten years. The hospital also hosts a live Q&A with gastroenterologists Pr Barbara Bournet and Pr Louis Buscail on Facebook and Instagram this Friday, November 20, at 12:30 p.m.

High-risk groups and warning signs need doctor review
People with long-standing type 2 diabetes, chronic pancreatitis — especially with a hereditary predisposition, for whom specific surveillance may be offered — or a strong family history should discuss individualized monitoring with their physician.
Any of the nine warning signs above, particularly painless jaundice, unexplained weight loss, or diabetes appearing suddenly in an adult without risk factors, warrants prompt medical consultation. The new oral therapy's severe skin and lesion toxicities mean it requires specialist oncology supervision; it is not a self-administered option.
The next dated milestone on record: the NeoPREDICT trial, now recruiting, will determine whether gene-expression-guided treatment becomes standard from diagnosis — and the O2CaPan pathway goes live across western Occitanie in early 2027.
References
- Journal des Femmes Santé — interview with Dr. Nelson Dusetti, Inserm/CRCM, November 19, 2026
- Sud Ouest, Destination Santé — “Cancer du pancréas : ces 9 signes qui doivent alerter”
- France 3 Régions Occitanie — reporting from the Centre de Recherches en Cancérologie de Toulouse, November 19, 2026
- La Dépêche — CHU de Toulouse O2CaPan care pathway launch, November 19, 2026
- Le Tribunal du Net — European authorization of the Revolution Medicines oral treatment, November 19, 2026
This article is informational and does not replace advice from a qualified healthcare professional.
Worth a look
- SAME Director Alberto Crescenti Honored in Argentina’s Congress for Public Health Leadership
- Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)
- K Hospital Honors 100 Teachers Battling Cancer on Teachers’ Day (time.news)